The Power of Quantitative Multiplexing- Combining TMT discovery and targeted label free workflows for biomarker analysis

Significance of the Topic

The identification and verification of plasma protein biomarkers play a critical role in diagnosing and monitoring diseases such as diabetes. Combining high-accuracy multiplexed discovery with rapid, label-free targeted verification addresses challenges of quantitative precision, sensitivity across a wide dynamic range, and throughput required for large-scale clinical studies.

Objectives and Study Overview

The study aimed to develop a streamlined workflow that employs Tandem Mass Tag (TMT) multiplexing for biomarker discovery in depleted human plasma, followed by transfer of peptide retention time information to a rapid, label-free verification method. The goal was to demonstrate high accuracy, robustness, and speed in both discovery and targeted phases, and to validate potential diabetes biomarkers identified in the discovery step.

Methodology and Instrumentation

A three-step workflow was implemented:

• Sample Preparation: Plasma from three healthy and three diabetic donors was depleted of abundant proteins, digested, and labeled with TMT6-plex reagents. Peptides were fractionated at high pH.
• Discovery Analysis: Eight fractions were analyzed on a Thermo Scientific Orbitrap Fusion MS using synchronous precursor selection (SPS) MS3 quantitation and an EASY-nLC 1200 nano-flow LC system.
• Targeted Verification: Unlabeled samples spiked with retention time standards (PRTC) were analyzed by 1D capillary-flow LC on a Thermo Scientific Q Exactive HF-X MS platform using parallel reaction monitoring (PRM) and full-scan detection.

Key instrumentation and software:

• Orbitrap Fusion MS with SPS-MS3
• Q Exactive HF-X hybrid quadrupole-Orbitrap MS
• Thermo Scientific EASY-nLC 1200 and UltiMate 3000 LC systems
• Proteome Discoverer 2.2 with Byonic search engine
• Sequence-Specific Retention Calculator (SSRCalc) for retention time prediction
• Skyline for PRM data processing

Main Results and Discussion

The TMT discovery workflow quantified 879 protein groups and 12 865 unique peptides, identifying 48 proteins with statistically significant differences (p < 0.05, log2 fold change > 0.5) between diabetic and normal samples. Known diabetes markers such as Talin, insulin-like growth factor-binding protein 4, and hepatocyte growth factor activator were among the candidates. Retention time prediction using SSRCalc and PRTC peptides enabled scheduling of nearly 180 targets for PRM. In the targeted assay, 30 of 48 proteins were successfully quantified within a one-hour run, achieving a throughput of 24 samples per day. Quantitation results correlated strongly with the TMT discovery data, confirming the reliability of the combined approach.

Benefits and Practical Applications of the Method

• High multiplexing in discovery reduces instrument time and improves quantitative precision.
• Retention time transfer accelerates targeted method development and ensures robust scheduling.
• Capillary-flow PRM offers enhanced throughput and reproducibility for routine verification in clinical studies.
• The workflow supports rapid progression from candidate identification to validation in tens to hundreds of samples.

Future Trends and Applications

Advances may include integration of higher-plex labeling reagents, machine learning-based retention time prediction, real-time data acquisition strategies, and application to other disease biomarker panels. Improvements in mass spectrometer scan speed and sensitivity will further enhance throughput and detection of low-abundance proteins in complex biological matrices.

Conclusion

The combined TMT discovery and label-free PRM verification workflow offers a robust, high-throughput solution for plasma biomarker research. It delivers accurate quantitation, rapid method transfer via retention time prediction, and streamlined validation of candidate proteins in clinical settings.

References

1. MacLean B, et al. Bioinformatics. 2010;26(7):966–968.
2. Renno W, et al. Medicina (Kaunas). 2006;42(2):147–163.
3. Brismar K, et al. J Clin Endocrinol Metab. 1994;79:872–878.
4. Fafalios A, et al. Nat Med. 2011;17(12):1577–1584.
5. Krokhin O, et al. Anal Chem. 2009;81(22):9522–9530.